Glenmark Pharmaceuticals, Boehringer Ingelheim subsidiary Roxane, Covidien's Mallinckrodt unit and six other companies received FDA warnings to stop selling 14 unapproved pain drugs that contain morphine, hydromorphone or oxycodone. Covidien said it will consider seeking FDA approval for its morphine product and comply with the agency's order, and Boehringer said it had submitted a U.S. application for a 4-mg dose of its hydromorphone hydrochloride tablets.

Full Story:
Reuters, USA Today

Related Summaries